CBD for Veterans: VA Rules, Drug Tests and What Research Shows

You may have wondered about CBD for PTSD, pain or sleep. At one VA pain clinic in North Dakota, 21 of 218 veterans surveyed (9.6%) said they used CBD, about half of them for pain (Voightman 2025). We recommend no products or doses.

At a glance

What VA policy says

VHA Directive 1315 (July 28, 2023) says VA providers must discuss marijuana with veterans who ask about it or report using it, document it, and must not deny VA services just because a veteran uses marijuana or takes part in a state-approved program. It bars VA providers from recommending, referring to, completing forms for, or registering veterans in state marijuana programs (VHA Directive 1315, 2023).

VA's fact sheet adds (VA 2023):

• Veterans will not be denied VA benefits because of marijuana use.
• Veterans are encouraged to discuss marijuana use with VA providers, who record it in the confidential medical record.
• VA clinicians may only prescribe FDA-approved medicines; most products containing THC, CBD or other cannabinoids are not FDA-approved.
• VA pharmacies may not fill medical marijuana prescriptions, and VA will not pay for it.
• Marijuana is prohibited on VA grounds, where federal law applies.
• VA employees are subject to drug testing.

Where CBD fits. The directive covers marijuana; its definition leaves out hemp, described as cannabis with no more than 0.3% delta-9 THC by dry weight (VHA Directive 1315, 2023). That 2018 definition's 0.3% delta-9 THC limit applies until December 11, 2026, unless Congress delays the change again (CRS 2026). As of November 2026, VA's list of health directives still showed the 2023 version of Directive 1315 as current, and we found no separate VA policy on hemp-derived CBD products in it (VHA directives list).

The one CBD prescription. The FDA says Epidiolex is the only FDA-approved drug containing CBD; it treats seizures of Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex (FDA 2024). Store-bought CBD products are not approved drugs, so VA clinicians cannot prescribe them. More: Is CBD FDA approved?

Rescheduling. On April 28, 2026, a Justice Department (DOJ) final rule moved FDA-approved drugs containing marijuana and state-licensed medical marijuana to Schedule III (DOJ 2026). As of October 28, 2026, according to CRS, all other marijuana remained in Schedule I while DOJ considered a broader change (CRS 2026). VA's directive (2023) and fact sheet (last updated August 2023) predate this change; as of November 2026, we found no updated VA policy.

Source type: VA directive (in force), VA fact sheet, DOJ final rule (final).

Service members and federal employees

Active duty and reserve. A February 26, 2020, Defense Department (DoD) memo ordered the military services to ban, by March 1, 2020, active-duty and reserve members from using products made or derived from hemp, including CBD, "regardless of the product's THC concentration" and regardless of how they are used (DoD 2020). It exempts FDA-approved cannabinoid drugs used with a valid prescription, such as dronabinol and Epidiolex, and durable goods such as rope or clothing (DoD 2020). Army rules, for example, list lotions, soaps and shampoos, according to Operation Supplement Safety (OPSS), a DoD education program (OPSS 2022a).

Source type: DoD memorandum (official order); OPSS summary (updated 2022).

Federal workplace drug tests. Federal agency urine tests look for a THC breakdown product (Δ9-THC carboxylic acid), with screening and confirmation cutoffs of 50 and 15 ng/mL, and oral fluid tests look for THC itself, not CBD; HHS left these panels unchanged in March 2026 (HHS 2026). In a study of six adults, single 100 mg doses of pure CBD did not produce a confirmed positive urine test, while vaporized CBD-dominant cannabis containing 3.7 mg of THC produced four confirmed positive samples (Spindle 2020).

Strength of evidence: one small laboratory study; the risk comes from THC in the product. Details: CBD and drug tests.

PTSD: what the research shows

The VA/DoD clinical practice guideline for PTSD (2023) makes a strong recommendation against cannabis or cannabis derivatives for treating PTSD. It cited a lack of well-designed trials and serious side effects, and rated confidence in the evidence as very low (VA/DoD 2023).

• VA-funded trial, San Diego: 96 veterans started prolonged exposure therapy plus CBD or placebo (the registry lists 136 enrolled). Three months after treatment ended (week 28), PTSD scores (0–80 scale) had fallen from 36.9 to 21.2 with CBD and from 35.1 to 21.9 with placebo. More people stopped early with CBD (23 of 50) than with placebo (15 of 46). These are summary results posted to the trial registry, not a peer-reviewed publication: no statistical comparison, and as of November 2026 no journal article (ClinicalTrials.gov NCT03518801).
• Single dose before trauma recall: In 33 adults with PTSD in Brazil, 300 mg of CBD did not reduce anxiety or discomfort during trauma recall more than placebo, though it lessened one measure of cognitive impairment (Bolsoni 2022a). An exploratory reanalysis found less anxiety only when the trauma was not sexual; three authors hold CBD-related patents (Bolsoni 2022b).
• Smoked cannabis in veterans: In 80 veterans, three weeks of smoked cannabis, including a high-CBD type (11% CBD, 0.5% THC), did no better than placebo; all groups improved (Bonn-Miller 2021).
• Pilot with Epidiolex: In 21 people getting two weeks of daily exposure therapy, clinician-rated scores a month later were lower with placebo, self-rated scores lower with CBD. Registry summary results only: no statistical comparison, and as of November 2026 no journal article (ClinicalTrials.gov NCT05132699).

Strength of evidence: low. The trials are small or short, and none showed a clear benefit over placebo. More in our PTSD guide.

Chronic pain, sleep and alcohol use

Chronic pain. In 15 of 16 randomized trials that used pharmaceutical-grade CBD for pain, CBD was no better than placebo (Moore 2024). The VA/DoD low back pain guideline (2022) found insufficient evidence to recommend for or against cannabis or cannabinoids (VA/DoD 2022). A placebo-controlled CBD trial planned for 468 veterans with chronic pain was listed as recruiting when last verified (May 2026), with completion estimated for December 2028 (ClinicalTrials.gov NCT06213233).

Strength of evidence: moderate, pointing to no benefit for pain. See chronic pain.

Sleep. In 30 adults with insomnia, 150 mg of CBD nightly for two weeks did not improve insomnia severity versus placebo, though a few secondary measures favored CBD (Narayan 2024). A systematic review found 34 studies, but only two focused on people with insomnia (Ranum 2023).

Strength of evidence: low; small, short studies. See insomnia.

Alcohol and other substances. In two small trials of adults with alcohol use disorder, including 30 who also had PTSD symptoms, CBD at 600–1,200 mg a day did not reduce drinking, craving or PTSD symptoms more than placebo, and 22.6% of those on CBD had side effects that limited the dose (Bogenschutz 2026). In an exploratory trial in people abstinent from heroin, three days of CBD at 400 or 800 mg reduced cue-triggered craving (Hurd 2019). The VA/DoD substance use guideline (2021) found insufficient evidence for any medicine for cannabis use disorder and called for more research on CBD (VA/DoD 2021).

Strength of evidence: low; no trial has shown that CBD reduces drinking. See CBD and alcohol and addiction.

Safety: medicines, liver and labels

Interactions. CBD moderately inhibits the liver enzyme CYP2C19, can raise levels of drugs it breaks down, and may make the anti-clotting drug clopidogrel less effective (Epidiolex label 2026). At prescription doses, Epidiolex can cause sleepiness, and alcohol and other sedating drugs may add to it (Epidiolex label 2026). Check your medicines in our drug interaction tool.

Liver. The Epidiolex label calls for liver tests before treatment and at 1, 3 and 6 months, and notes a higher risk with valproate (Epidiolex label 2026). In an FDA trial of 201 healthy adults, 5.6% of those taking CBD for four weeks, and none on placebo, had liver enzymes above three times normal (Florian 2025).

Strength of evidence: moderate for liver enzyme rises.

Mood. Like all seizure medicines, Epidiolex carries a class warning, based on pooled trials of 11 antiepileptic drugs, that these drugs increase the risk of suicidal thoughts or behavior; patients should be watched for new or worsening depression (Epidiolex label 2026). Whether it applies to store-bought CBD is unknown. If you have thoughts of suicide, contact VA's crisis services or emergency services right away.

Labels. In 56 CBD gummy products, 39% contained delta-9 THC, and nine had more than 0.4 mg in a single gummy (Johnson 2025). THC was found in 35% of 105 topical CBD products; four of these were labeled THC-free (Spindle 2022). See reading labels.

Strength of evidence: product testing studies; they show labels can be wrong, not how often harm occurs.

Federal law and the 2026 changes

From November 12, 2026, products containing cannabinoids that the cannabis plant cannot produce naturally no longer count as hemp (Pub. L. 119-37; Pub. L. 119-103). CBD occurs naturally in the plant (OPSS 2022b). Starting December 11, 2026, unless Congress delays it again, the rest of the new definition applies: cannabinoids synthesized or manufactured outside the plant are excluded, THC is counted as total THC including THCA, and final hemp-derived cannabinoid products are limited to 0.4 mg of total THC per container (Pub. L. 119-37; Pub. L. 119-103; CRS 2026). Both are enacted statutes. Details: CBD laws in the US and what changes when.

When to talk to a VA provider or pharmacist

Tell your VA provider or pharmacist before starting CBD, and bring the product, especially if you take a blood thinner, antidepressant, sleep or anxiety medicine, opioid or seizure medicine; have liver disease or drink heavily; or are in PTSD or substance use treatment. Ask whether liver tests make sense. If you are drug tested, weigh the THC risk.

Frequently asked questions

References